Bovine Syncytial Virus: Veterinary Reference

Overview and Taxonomy of Bovine Syncytial Virus: Veterinary Reference

Introduction to the Pathogen and Its Clinical Significance

Bovine respiratory syncytial virus (BRSV), formally classified as Bovine orthopneumovirus according to the International Committee on Taxonomy of Viruses (ICTV) nomenclature, stands as one of the most economically consequential viral pathogens affecting cattle populations worldwide [2, 15, 20]. This enveloped, negative-sense, single-stranded RNA virus is a primary etiological agent within the bovine respiratory disease (BRD) complex, a multifactorial syndrome that represents the leading cause of morbidity and mortality in young calves and feedlot cattle [8, 24]. The virus exhibits a remarkable capacity for inducing acute respiratory disease, particularly in calves under one year of age, and its seroprevalence in intensively managed livestock operations frequently reaches 60–90%, underscoring its ubiquity and epizootiological importance [2, 9]. Indeed, serological surveys conducted across diverse geographic regions, from European dairy operations to Turkish beef herds, consistently demonstrate that the vast majority of animals encounter this pathogen early in life, with maternally derived antibodies (MDA) providing only transient and often incomplete protection [6, 9, 21]. The clinical consequences of BRSV infection range from subclinical disease, detectable only through molecular or transcriptomic biomarkers, to fulminant bronchointerstitial pneumonia characterized by necrotizing bronchiolitis, syncytial giant cell formation, and significant pulmonary consolidation [3, 8, 22]. The economic toll imposed by BRSV is profound, extending beyond acute mortality and treatment costs to include persistent reductions in weight gain and feed conversion efficiency that may last for eight months or more following an outbreak [14]. This sustained negative impact on production parameters, even in animals that exhibit only mild or subclinical disease, underscores the insidious nature of BRSV infection and the critical need for robust diagnostic and control strategies.

Taxonomic Classification and Phylogenetic Relationships

BRSV belongs to the family Pneumoviridae, genus Orthopneumovirus, a taxonomic reassignment from its former placement within the Paramyxoviridae family, reflecting significant advances in molecular phylogenetic analysis [20]. The virus is the bovine counterpart of human respiratory syncytial virus (HRSV), and these two pathogens share an extraordinary degree of genetic, antigenic, and pathogenic similarity. Both viruses exhibit analogous genomic organization, encode homologous structural and non-structural proteins, and induce nearly identical patterns of respiratory pathology in their respective hosts [11, 20]. Phylogenetic analyses based on sequences of the fusion (F) glycoprotein and attachment (G) glycoprotein genes have delineated BRSV into multiple antigenic subgroups and genotypes, with subgroup III emerging as a predominant lineage circulating in many regions, including Turkey, Brazil, and parts of Europe [5, 7, 9]. Importantly, molecular characterization of field isolates has revealed ongoing viral evolution, with new amino acid substitutions in the G protein, such as P89S, D115G, and S165L, demonstrating that BRSV continues to diverge antigenically [9]. This genetic plasticity has implications for vaccine design and diagnostic assay development, as strain-specific variations may influence cross-protection and detection efficiency [11, 20]. The close phylogenetic relationship between BRSV and HRSV has also spurred collaborative research efforts between human and veterinary medicine, particularly in vaccine development, where knowledge of immune responses and vaccine platforms can be cross-utilized; however, patent analyses indicate that such cross-fertilization remains surprisingly limited [20].

Virion Structure, Genomic Organization, and Protein Functions

The BRSV virion is a pleomorphic, enveloped particle approximately 150–300 nm in diameter, decorated with surface glycoprotein spikes that mediate host cell attachment and entry [20]. The viral genome comprises approximately 15,000 nucleotides of negative-sense, single-stranded RNA, organized into ten genes that encode eleven distinct proteins [11]. The major surface glycoproteins, the fusion (F) protein and the attachment (G) protein, are the primary targets of the host neutralizing antibody response and are thus critical components of vaccine formulations [11, 18]. The F protein mediates viral entry by catalyzing membrane fusion between the viral envelope and the host cell plasma membrane, a process that requires proteolytic cleavage and is essential for infectivity. Recombinant expression of the BRSV F1 protein in Escherichia coli systems has demonstrated its capacity to elicit robust antibody responses in laboratory animal models, confirming its utility as a protective immunogen [18]. The G protein, in contrast, is a heavily glycosylated type II transmembrane protein responsible for initial attachment to host cell glycosaminoglycans. The extensive O-linked glycosylation of the G protein contributes to immune evasion by masking conserved epitopes and driving antigenic variation, a mechanism that complicates the development of broadly protective vaccines [9, 20].

Beyond the surface glycoproteins, the BRSV genome encodes several internal proteins that orchestrate replication and modulate host immune responses. The nucleocapsid (N) protein encapsidates the viral RNA, forming the helical ribonucleoprotein complex that serves as the template for transcription and replication [1, 13, 15]. The N gene is highly conserved among BRSV isolates, making it an ideal target for molecular diagnostics such as reverse-transcriptase quantitative PCR (RT-qPCR) assays [1, 12, 13]. The phosphoprotein (P) and the large polymerase (L) protein, along with the transcription factor M2-1, constitute the viral RNA-dependent RNA polymerase complex [11]. The M2-1 protein is essential for processive transcription and has been explored as a subunit vaccine antigen, capable of inducing cell-mediated immune responses in calves [11]. The small hydrophobic (SH) protein, while non-essential for viral replication in vitro, appears to play a role in modulating host cell apoptosis and inflammatory responses; deletion of the SH gene in a recombinant BRSV vaccine strain (ΔSHrBRSV) resulted in attenuation while preserving immunogenicity [11]. The matrix (M) protein underlies the viral envelope, providing structural integrity to the virion and coordinating assembly. The non-structural proteins NS1 and NS2, though absent from the mature virion, are critical virulence factors that antagonize the host type I interferon response, thereby facilitating viral replication in vivo and contributing to pathogenicity [20].

Viral Replication Cycle and Pathogenesis

The replication cycle of BRSV is initiated when the G protein mediates attachment to the apical surface of ciliated airway epithelial cells, followed by F protein-driven fusion with the host cell membrane at neutral pH, releasing the viral ribonucleoprotein complex into the cytoplasm [20]. Primary transcription of the negative-sense genome by the viral polymerase yields positive-sense mRNAs that are translated into viral proteins. Replication proceeds through the synthesis of a full-length positive-sense antigenome, which serves as a template for the production of progeny negative-sense genomes. The accumulation of viral proteins and genomes at the plasma membrane drives budding, with the M protein orchestrating the final stages of assembly and egress. The cytopathic effect (CPE) of BRSV in cell culture is characterized by the formation of large, multinucleated syncytia, a consequence of F protein-mediated cell-to-cell fusion that facilitates viral spread without exposure to extracellular neutralizing antibodies [7, 22].

In the bovine host, BRSV infection is largely confined to the respiratory tract, where it preferentially infects ciliated epithelial cells of the nasal mucosa, trachea, bronchi, and bronchioles [16, 22]. The virus can be recovered from nasal swabs, tracheal washes, bronchoalveolar lavage fluid, and postmortem lung tissue [10, 15]. Pathologically, BRSV induces necrotizing bronchiolitis with epithelial sloughing, airway obstruction by cellular debris and inflammatory exudate, and the formation of characteristic syncytial giant cells within alveoli [16, 22]. Immunohistochemical detection of BRSV antigens in formalin-fixed, paraffin-embedded lung tissues reveals that viral proteins are predominantly localized to bronchiolar epithelial cells and, less frequently, alveolar epithelial cells, with occasional staining in inflammatory cells and cellular debris within airway lumens [16]. The host immune response to BRSV is a double-edged sword: while cytotoxic T lymphocytes and neutralizing antibodies are essential for viral clearance, the exuberant inflammatory response, including the recruitment of neutrophils, macrophages, and the release of pro-inflammatory cytokines, contributes significantly to the immunopathology of BRSV-associated pneumonia [4, 8, 23]. Transcriptomic analyses of bronchial lymph nodes and whole blood from experimentally infected calves have unveiled a robust activation of interferon signaling pathways, pathogen recognition receptor pathways, and granulocyte adhesion and diapedesis pathways, underscoring the complexity of the host-virus interaction [4, 8]. MicroRNA profiling has further elucidated the regulatory networks governing these immune responses, with differentially expressed miRNAs predicted to target genes involved in T cell responses, apoptosis of leukocytes, and innate immune signaling [4].

Antigenic Subgroups and Genetic Variability

Antigenic and genetic characterization of BRSV field isolates has revealed the existence of multiple subgroups and genotypes, with the most widely recognized classification distinguishing subgroups I, II, III, and IV based on reactivity with monoclonal antibodies and phylogenetic analysis of the G glycoprotein gene [5, 7, 9]. Subgroup III, which includes the Snook and 220-60 reference strains, appears to be the predominant circulating lineage in many parts of the world, including Europe, the Americas, and the Middle East [7, 9]. In Turkey, molecular characterization of BRSV isolates from respiratory disease outbreaks has consistently placed field strains within subgroup III, although they often occupy distinct phylogenetic branches, indicating regional evolution and diversification [5, 7, 9]. The G protein, in particular, exhibits a high degree of sequence variability, driven by selective pressure from host immune responses. This variability is concentrated in the central hypervariable region of the ectodomain, where nucleotide substitutions can alter glycosylation patterns and potentially modify antigenic epitopes [9]. The emergence of novel substitutions, such as P89S, D115G, and S165L in Turkish isolates, highlights the ongoing evolution of BRSV and raises questions about the long-term efficacy of existing vaccines [9]. In contrast, the F and N proteins are highly conserved across BRSV isolates, a feature that has been exploited for diagnostic targeting using RT-qPCR assays [1, 12, 13]. The choice of target gene is therefore critical: while the N gene offers broad detection capability, the G gene provides discriminatory power for molecular epidemiology and tracking of strain emergence.

Epidemiological Context and Role in the Bovine Respiratory Disease Complex

BRSV does not act in isolation but rather operates within the complex ecological and pathological framework of the BRD complex, interacting synergistically with other viral and bacterial pathogens [24]. Primary infection with BRSV compromises the innate immune defenses of the respiratory tract, disrupting mucociliary clearance and damaging the epithelial barrier, thereby creating a permissive environment for secondary bacterial invasion by opportunistic pathogens such as Mannheimia haemolytica, Pasteurella multocida, and Mycoplasma bovis [23, 24]. Co-infection studies have demonstrated that BRSV followed by bacterial challenge results in more severe clinical disease, altered lung transcriptomic profiles, and enhanced inflammatory responses compared to either pathogen alone [23]. The interplay between BRSV and other respiratory viruses, such as bovine parainfluenza virus type 3 (BPIV3), bovine herpesvirus 1 (BoHV-1), and bovine viral diarrhea virus (BVDV), further complicates the clinical picture. Epidemiological surveys have documented co-infections involving multiple viral agents in a substantial proportion of respiratory disease cases, with mixed infections detected in up to 25% of diseased cattle in some studies [12, 17]. Indeed, a study in the Kangra district of Himachal Pradesh found that 56.67% of necropsied calves were positive for BRSV, often in combination with BoHV-1, BPIV3, or BVDV [17]. This high prevalence underscores the importance of multiplex diagnostic approaches for accurate etiological diagnosis and for guiding appropriate intervention strategies [1, 12, 13].

The economic impact of BRSV is magnified by its ability to cause disease in both dairy and beef production systems, affecting calves, replacement heifers, and adult cattle under stress [2, 9, 14]. Outbreaks are often associated with management practices that facilitate viral transmission, including housing of mixed-age groups, commingling of animals from different sources, transport stress, and weaning. The virus is shed in high concentrations in nasal secretions, and transmission occurs via direct contact or aerosolization [5, 10]. Once introduced into a herd, BRSV can establish latent or persistent foci, contributing to recurrent outbreaks and making eradication challenging [2]. The global distribution of BRSV, with seroprevalence rates of 70–90% in countries with intensive livestock production, highlights its status as a truly ubiquitous pathogen that demands coordinated surveillance and control efforts [2, 9]. The World Organisation for Animal Health (WOAH) recognizes the significance of BRD pathogens, and national veterinary authorities in many endemic regions are increasingly prioritizing BRSV within their epizootiological surveillance programs [2, 19]. In regions such as Kazakhstan, where official data on BRSV distribution are lacking, the risk of hidden virus circulation remains substantial, and the inclusion of BRSV in national surveillance frameworks is urgently recommended [2].

Molecular Pathogenesis and Virulence Determinants of Bovine Syncytial Virus

Bovine syncytial virus, formally classified as Bovine orthopneumovirus and more commonly referred to as bovine respiratory syncytial virus (BRSV), is a member of the Pneumoviridae family, genus Orthopneumovirus [15, 20]. Its molecular pathogenesis is a complex, multi-stage process that begins with viral entry into the host respiratory epithelium and culminates in profound immunopathology and tissue damage. The virus is genetically and antigenically closely related to human respiratory syncytial virus (HRSV), sharing a similar genomic organization and a comparable repertoire of virulence determinants that dictate its ability to infect, replicate, and subvert the bovine host's defenses [20]. Understanding these molecular mechanisms is critical for developing effective vaccines and therapeutic interventions, as BRSV remains a primary viral incitant of the bovine respiratory disease complex (BRDC), causing significant economic losses globally [2, 9, 14].

Structural and Genomic Basis of Virulence

The BRSV genome is a single-stranded, negative-sense RNA molecule approximately 15 kilobases in length, encoding 11 major proteins. Among these, the surface glycoproteins, the attachment glycoprotein (G), the fusion glycoprotein (F), and the small hydrophobic (SH) protein, are the principal determinants of viral entry, cell-to-cell spread, and immune evasion. The nucleocapsid (N) protein, while primarily structural, also plays a role in replication efficiency and is a common target for molecular diagnostics due to its high conservation [1, 15].

The G glycoprotein is the primary attachment protein, mediating viral binding to host cell surface receptors. Its genetic variability is a hallmark of BRSV evolution and a key virulence determinant. Phylogenetic analyses of the G gene have classified BRSV into distinct subgroups (e.g., subgroup III), with field isolates demonstrating ongoing antigenic drift [5, 7, 9]. For instance, Turkish field isolates have been shown to harbor specific amino acid substitutions in the G protein, such as P89S, D115G, and S165L, which may alter receptor binding affinity or facilitate escape from neutralizing antibodies [9]. This continuous evolution of the G protein contributes to the virus's ability to cause recurrent outbreaks in herds, even in the presence of pre-existing immunity [2, 9]. The G protein is also heavily glycosylated, a feature that can shield critical epitopes from antibody recognition, further complicating host immune clearance.

The F glycoprotein is responsible for the fusion of the viral envelope with the host cell membrane, a process essential for viral entry. It also drives the formation of syncytia, the characteristic multinucleated giant cells that give the virus its name, by mediating fusion between infected and adjacent uninfected cells [7, 22, 25]. The F protein is synthesized as an inactive precursor (F0) that must be cleaved by host cell proteases into the disulfide-linked F1 and F2 subunits to become fusogenically active. This cleavage is a critical activation step and a potential target for host antiviral defenses. The F protein is a major target of the host neutralizing antibody response, and its conservation across BRSV and HRSV has made it a focus for cross-protective vaccine development [11, 18]. Recombinant F protein-based subunit vaccines have shown promise in eliciting protective immunity, although the quality and durability of the response are highly dependent on the adjuvant and delivery system used [11, 18].

The SH protein is a small, non-glycosylated transmembrane protein whose precise function has been enigmatic. However, studies using a recombinant BRSV with a deletion of the SH gene (ΔSHrBRSV) have provided profound insights into its role as a virulence determinant. Calves immunized with ΔSHrBRSV demonstrated almost complete clinical and virological protection against a virulent BRSV challenge, indicating that the SH protein is not essential for replication but is critical for full virulence in vivo [11]. The SH protein is thought to function as a viroporin, forming ion channels in the host cell membrane that can inhibit apoptosis and modulate the host inflammatory response. Its deletion likely attenuates the virus by reducing its ability to counteract host cell death pathways and by altering the balance of cytokine signaling, thereby allowing for a more effective immune response without causing severe disease [11]. This makes the SH gene a prime target for the development of live-attenuated vaccines that are both safe and immunogenic.

Host Cell Entry and Replication Cycle

The molecular pathogenesis of BRSV begins with the attachment of the G protein to host cell surface glycosaminoglycans, such as heparan sulfate. This initial, low-affinity interaction is followed by a more specific engagement with cellular receptors, including nucleolin and the CX3 chemokine receptor 1 (CX3CR1). The interaction between the G protein and CX3CR1 is particularly significant, as it not only facilitates viral entry but also mimics the action of the natural chemokine fractalkine. This molecular mimicry allows BRSV to modulate the host immune response, potentially skewing it away from an effective antiviral state and toward a pro-inflammatory, pathogenic response [4, 8].

Following attachment, the F protein undergoes a dramatic conformational change, driving the fusion of the viral and host cell membranes and releasing the viral ribonucleoprotein complex into the cytoplasm. The viral RNA-dependent RNA polymerase, composed of the L (large) protein and the phosphoprotein (P), then initiates transcription and replication. The N protein encapsidates the viral RNA, forming the template for the polymerase complex [1, 15]. The replication cycle is rapid, with new viral particles assembling at the plasma membrane and budding from the cell, often without causing immediate cell lysis. However, the accumulation of viral proteins and the formation of syncytia lead to significant cytopathology, including ciliostasis, necrosis of bronchiolar epithelial cells, and sloughing of the airway epithelium [16, 22].

Immunopathogenesis and Host Response Modulation

The clinical disease associated with BRSV is not solely a result of direct viral cytopathology; rather, it is largely driven by an aberrant and exaggerated host immune response. This immunopathogenesis is a central feature of the disease. The virus triggers a robust innate immune response, characterized by the upregulation of pro-inflammatory cytokines and chemokines. Transcriptomic analyses of bronchial lymph nodes and whole blood from BRSV-infected calves have revealed a massive dysregulation of gene expression, with hundreds of differentially expressed genes (DEGs) involved in interferon signaling, pathogen recognition receptor pathways, and cytotoxic T-cell responses [3, 4, 8].

Key pathways identified include the interferon (IFN) signaling pathway, which is a double-edged sword. While type I IFNs are crucial for establishing an antiviral state, their over-exuberant production can contribute to tissue damage. Similarly, the granzyme B signaling pathway, indicative of cytotoxic T lymphocyte (CTL) activity, is essential for clearing infected cells, but excessive CTL activity can exacerbate lung pathology [8]. The virus also modulates the host response at the post-transcriptional level through the induction of microRNAs (miRNAs). In the bronchial lymph node, BRSV infection leads to the differential expression of 119 miRNAs, which in turn regulate a network of target genes involved in granulocyte adhesion and diapedesis, interferon signaling, and the recognition of pathogens [4]. This miRNA-mediated regulation represents a sophisticated layer of host-pathogen interaction, where the virus may exploit or subvert host regulatory mechanisms to its advantage.

A hallmark of BRSV pathogenesis is its ability to suppress or evade effective adaptive immunity, particularly in young calves with immature immune systems or in the presence of maternally derived antibodies (MDA). The virus can infect and modulate the function of antigen-presenting cells, such as dendritic cells and macrophages, impairing their ability to prime naive T cells. Furthermore, the G protein's CX3CR1 mimicry can directly interfere with chemokine signaling, potentially altering the trafficking and activation of immune cells to the site of infection [4, 8]. This immune subversion contributes to the high susceptibility of young calves and the difficulty in inducing robust, long-lasting protective immunity through vaccination, especially in the face of MDA [6, 11].

Role in the Bovine Respiratory Disease Complex and Synergistic Pathogenesis

BRSV rarely acts alone. Its pathogenic significance is amplified by its role as a primary viral initiator of the BRDC, predisposing the lung to secondary bacterial infections, most notably with Mannheimia haemolytica and Pasteurella multocida [12, 23, 24]. The molecular basis for this synergy is multifaceted. BRSV-induced damage to the mucociliary escalator and the respiratory epithelium compromises the physical barrier of the lung. Viral infection also alters the expression of adhesion molecules on the surface of epithelial cells, facilitating the adherence of bacteria. Furthermore, BRSV can suppress the phagocytic and bactericidal functions of alveolar macrophages and neutrophils, creating an immunocompromised environment that allows bacteria to proliferate unchecked [23, 24].

Experimental co-infection models have demonstrated that BRSV followed by Pasteurella multocida results in a more severe clinical disease and a distinct transcriptional profile in the lung compared to either pathogen alone. The co-infection leads to a dysregulated inflammatory response, with altered expression of genes involved in glutathione metabolism and lung repair, suggesting that the virus not only damages the lung but also impairs its ability to heal [23]. This synergistic pathogenesis is the primary driver of the severe fibrinous pleuropneumonia that is the hallmark of terminal BRDC, underscoring the critical importance of controlling BRSV infection to prevent the cascade of secondary bacterial disease [22, 24]. The high seroprevalence of BRSV in cattle populations worldwide, often exceeding 60-70%, highlights the constant threat this virus poses as a gatekeeper for more severe respiratory disease [2, 9, 25].

Epidemiology, Seroprevalence, and Risk Factors in Cattle Populations

Global Distribution and Endemicity of Bovine Respiratory Syncytial Virus

Bovine respiratory syncytial virus (BRSV) is recognized as a ubiquitous pathogen of cattle, exhibiting a truly global distribution that mirrors the intensity of livestock production systems. The epidemiological footprint of BRSV is vast, with serological evidence of infection reported across every continent where cattle are raised, from the intensive feedlots of North America to the pastoral dairy systems of Europe and the emerging livestock sectors in Asia, Africa, and South America. The virus’s ability to establish and maintain endemic circulation within herds is a defining characteristic, driven by its capacity for rapid transmission, the presence of persistently infected or latently shedding animals, and the constant influx of naïve calves that replenish the susceptible population. The economic consequence of this endemicity is staggering, as BRSV is a primary viral trigger within the bovine respiratory disease (BRD) complex, often serving as the initial insult that predisposes the lower respiratory tract to secondary bacterial colonization, leading to severe bronchopneumonia, increased mortality, reduced weight gain, and substantial treatment costs [9, 14, 25].

The global seroprevalence of BRSV is remarkably high, consistently reported in the range of 60% to 90% in areas with intensive cattle husbandry. A comprehensive retrospective analysis of serological testing performed by the FGBI “ARRIAH” Reference Laboratory for Cattle Diseases in Russia between 2017 and 2018 documented a seroprevalence of 60% in animals on dairy farms, confirming that BRSV infection is a persistent and widespread challenge even in regions with established veterinary oversight [25]. This figure is corroborated by a recent review of epizootiological features, which notes that seroprevalence among cattle populations in countries with intensive livestock farming frequently reaches 70–90% [2]. These high seroprevalence rates underscore the near-universal exposure of cattle to BRSV, particularly in environments where animals are housed in close confinement, facilitating aerosol transmission. The virus is shed in high concentrations in nasal secretions and exhaled droplets, and the basic reproduction number (R0) within a naïve herd can be substantial, leading to rapid spread and high attack rates, especially among young calves [3, 6]. The concept of endemic stability, where a high proportion of adult animals are seropositive, is critical to understanding BRSV epidemiology; in such herds, clinical disease is often limited to calves under one year of age who have lost their maternally derived antibodies (MDA) but have not yet mounted a robust active immune response [2, 25].

Regional Seroprevalence Data and Molecular Epidemiology

Detailed regional studies provide a granular view of BRSV’s seroprevalence and highlight the influence of local management practices, climate, and animal demographics. A large-scale cross-sectional study conducted in the inner Aegean region of Turkey analyzed 557 serum samples from 43 cattle herds between 2018 and 2019 using a commercial indirect-ELISA. The results were striking: all 43 herds (100%) had at least one seropositive animal, and after adjustment for assay sensitivity and specificity, the overall true seropositivity was calculated at 58.48% (95% CI: 53.32–63.47) [9]. This herd-level prevalence of 100% underscores the ubiquitous nature of BRSV exposure in the region, suggesting that the virus circulates continuously even in herds that may not report clinical outbreaks. The study also performed molecular characterization of BRSV isolates from nasal swabs, revealing that the circulating field strains belonged to subgroup III. Critically, these Turkish strains displayed three novel amino acid substitutions (P89S, D115G, and S165L) in the attachment glycoprotein (G) chain compared to reference isolates, providing direct evidence that BRSV is under continuous evolutionary pressure and that antigenic drift may contribute to the ability of the virus to reinfect partially immune populations [9].

In South America, retrospective studies have historically underreported BRSV due to a reliance on less sensitive diagnostic methods. However, a seminal investigation using immunohistochemistry (IPX) on archived histological specimens from Brazil revealed that 24.4% of calf pneumonia cases were positive for BRSV antigens, with the majority of positive cases occurring in young dairy calves between 2 and 12 months of age [16]. This study was critical in demonstrating that BRSV is a significant cause of bronchointerstitial pneumonia in Brazilian cattle, a finding that might otherwise have been masked by a focus on bacterial pathogens. The detection of BRSV antigens primarily in bronchiolar epithelial cells and, less frequently, in alveolar syncytial giant cells, confirmed the virus’s tropism for the lower respiratory tract and its role in initiating the characteristic histopathological lesions associated with BRD [16]. Similarly, in Turkey, the first isolation and molecular characterization of indigenous BRSV strains from beef cattle that died from respiratory distress confirmed the presence of subgroup III viruses, with sequence analysis showing 99.49% nucleotide and 99.22% amino acid identity to another Turkish strain (KY499619), highlighting the circulation of a genetically distinct, autochthonous viral lineage [7]. This work, alongside another study from eastern Turkey which detected BRSV RNA in 1.29% of nasal swab and lung samples, provides foundational molecular epidemiological data for a region where BRSV was previously under-documented [5].

The situation in Kazakhstan is particularly concerning. A recent review emphasizes that official data on BRSV distribution in the Republic of Kazakhstan are currently lacking, despite the country’s close trade and epizootic links with neighboring regions where the virus is known to circulate. Given the high frequency of respiratory diseases of unknown etiology in Kazakh cattle, there is a substantial risk of hidden virus circulation, and the authors strongly recommend that BRSV be included in national epizootiological surveillance programs [2]. This gap in surveillance is a classic example of the “iceberg” phenomenon, where the reported incidence of clinical disease represents only a small fraction of the true infection burden, with most infections remaining subclinical or undiagnosed.

Risk Factors for BRSV Infection and Transmission

The risk factors associated with BRSV infection are multifactorial, encompassing host, pathogen, environmental, and management-related variables. Understanding these factors is paramount for designing effective control strategies, including targeted vaccination and biosecurity protocols. The most comprehensive risk factor analysis from the available literature comes from the cross-sectional study in the inner Aegean region of Turkey, which employed a generalized estimating equation (GEE) model to identify significant associations [9].

Age is consistently identified as a dominant risk factor. In the Turkish study, age was positively associated with BRSV infection (OR = 2.36, p = 0.001), indicating that the odds of being seropositive increase with age [9]. This is a well-established pattern: calves are born seronegative and are initially protected by MDA acquired from colostrum. As these antibodies wane over the first 2 to 6 months of life, calves become highly susceptible to infection. Clinical disease is most frequently observed in animals between 2 and 12 months of age, a period often referred to as the “window of susceptibility” [16, 25]. Older animals are typically seropositive due to prior natural exposure, but their immunity is not sterile and can be boosted by re-exposure, allowing the virus to persist in the herd. The FGBI “ARRIAH” study explicitly noted that calves under one year of age are the most susceptible to BRSV [25], a finding that aligns with experimental challenge studies where young Holstein-Friesian calves inoculated with BRSV (10^3.5 TCID50/ml × 15 ml) developed clinical signs, albeit sometimes mild, and exhibited profound transcriptomic changes in both bronchial lymph nodes and whole blood [3, 4, 8].

Herd size and herd type are powerful management-related risk factors. The Turkish study found that increasing herd size was the strongest predictor of BRSV seropositivity (OR = 10.32, p < 0.001), while herd type (i.e., dairy vs. beef) was also highly significant (OR = 8.97, p < 0.001) [9]. Large herds, particularly dairy operations, inherently harbor a larger number of susceptible individuals (calves) and provide continuous opportunities for viral introduction and spread through the mixing of age groups, the purchase of replacement heifers, and the stress of management procedures. The closed, confined environment of a modern dairy barn, with poor ventilation and high stocking density, creates ideal conditions for aerosol transmission of BRSV. In contrast, beef cow-calf operations often have more extensive, open-range management, which may reduce the rate of transmission, although outbreaks can still occur during weaning and feedlot finishing. The importance of herd-level factors is further emphasized by the finding that the presence of a past history of respiratory disease in the herd was a significant risk factor (OR = 4.06, p < 0.001) [9], suggesting that once BRSV is introduced, it tends to become endemic, causing recurrent outbreaks.

Seasonality and housing conditions play a permissive role in BRSV epidemiology. While BRSV can be detected year-round, outbreaks are most commonly reported in the autumn, winter, and early spring, correlating with the period when cattle are housed indoors in close confinement. The stress of indoor housing, combined with poor air quality (high ammonia, dust, and pathogen load), compromises mucociliary clearance and local immune defenses, facilitating viral entry and replication. The spatial distribution of outbreaks within a facility is often non-random, with infection spreading rapidly from pen to pen via fomites (e.g., shared feeding equipment, contaminated clothing of personnel) and via direct animal-to-animal contact. The phenomenon of “asymptomatic carriage” is a critical epidemiological feature; animals that have recovered from acute infection may continue to shed virus at low levels, or the virus may persist in a latent state in lymphoid tissues, reactivating during periods of immunosuppression (e.g., parturition, transport, nutritional stress) [2]. This carrier state complicates control measures and contributes to the recurrent nature of outbreaks in enzootic herds.

Co-infection with other pathogens is a major modifier of BRSV epidemiology and disease severity. BRD is a polymicrobial syndrome, and BRSV rarely acts alone. A large study evaluating the detection rates of multiple pathogens using a multiplex qPCR assay on 224 clinical samples from naturally diseased cattle reported that BRSV was detected in 7.59% of cases, but the mixed infection rate with two or more of the six targeted pathogens (BRSV, BPIV3, BVDV, BAV3, Mycoplasma bovis, and IBRV) was 25% (56/224) [12]. This indicates that BRSV is frequently part of a polymicrobial challenge. The classic pathogenesis of BRD often begins with a viral infection, BRSV, bovine parainfluenza virus type 3 (BPIV3), or bovine herpesvirus-1 (BoHV-1), that damages the ciliated epithelial lining of the respiratory tract, impairs mucociliary clearance, and suppresses local immune responses, thereby paving the way for secondary bacterial invasion by Mannheimia haemolytica, Pasteurella multocida, or Histophilus somni [10, 24]. Other studies have confirmed high rates of BRSV co-infection with BoHV-1 (56.67% each) and BPIV3 (46.67%) in necropsied calves from India [17]. The synergistic interaction between BRSV and bacterial pathogens significantly increases the severity of pneumonia, morbidity, and mortality, transforming a mild viral infection into a life-threatening bronchopneumonia.

Production and Economic Impact as an Epidemiological Outcome

The epidemiological significance of BRSV is ultimately measured by its profound economic impact. A landmark Norwegian study tracked individual weight gain and feed conversion in bulls over an eight-month period following a natural BRSV outbreak. The results demonstrated that bulls which developed severe clinical signs during the outbreak had a weight/age ratio that was 0.04–0.10 lower, and their growth rate remained significantly depressed for at least 8 months compared to unaffected cohorts. Furthermore, apparently healthy bulls that were merely exposed during the outbreak exhibited a reduction in growth rate of 111 g/day and required an additional 23 days to reach reference slaughter weight. Feed conversion was also impaired by 79 g of weight gain per kilogram of concentrate consumed [14]. These findings are critical because they reveal that the economic consequences of BRSV extend far beyond the acute mortality and treatment costs; they include a long-term, persistent reduction in growth performance and feed efficiency, even in animals that never showed clinical signs. This “hidden” production loss is often grossly underestimated in cost-benefit analyses of BRD control programs.

Diagnostic Surveillance and the Interpretation of Seroprevalence Data

Accurate epidemiological interpretation of BRSV seroprevalence is heavily dependent on the diagnostic methods used. As noted in the literature, the development and validation of sensitive molecular tools, including monoplex and multiplex RT-qPCR and recombinase polymerase amplification (RPA) assays, have revolutionized surveillance efforts [1, 12, 13, 26]. For instance, a field-validated multiplex RT-qPCR assay for BRSV and BPIV3 demonstrated a diagnostic sensitivity that was 2.4 times greater than traditional virus isolation, detecting BRSV in 17% of clinical cases via multiplex and 19% via monoplex [1]. Another one-step multiplex real-time RT-PCR assay, targeting the BRSV nucleocapsid gene, showed a sensitivity of 97% in detecting 10^2 copies of the target, far outperforming both virus isolation and immunofluorescence [13]. The use of molecular diagnostics allows for the detection of viral RNA not only in actively sick animals but also in subclinical shedders, providing a more accurate picture of the true prevalence of infection within a herd [10].

Serological surveys, traditionally reliant on ELISA or virus neutralization tests, provide a record of past exposure but cannot distinguish between infected and vaccinated animals (DIVA). The development of DIVA-compatible vaccines, such as the SH gene-deleted recombinant BRSV (ΔSHrBRSV) or subunit vaccines based on HRSV N, P, and M2-1 proteins, is a significant advance that will enable improved sero-epidemiological monitoring of vaccine efficacy and viral circulation [11]. The World Organisation for Animal Health (WOAH) emphasizes the importance of robust surveillance and diagnostic capacity for economically significant pathogens like BRSV, and the data from these studies support the integration of molecular monitoring into national and regional control programs.

The data from controlled vaccine trials also provide crucial epidemiological insights. The presence of MDA is a known risk factor for vaccine failure, yet a pivotal trial demonstrated that a live intranasal BRSV/BPIV3 vaccine was efficacious in young calves even in the presence of high levels of MDA. In this study, vaccinated calves, regardless of their MDA status, had significantly lower clinical scores and reduced nasal shedding after challenge compared to unvaccinated controls [6]. This finding suggests that vaccination can be used effectively even in herds where MDA is prevalent, which is the norm, and that intranasal delivery may circumvent the neutralizing effect of systemic MDA. The serological survey component of that trial, which tested 254 samples from calves across five European countries (Germany, Spain, Italy, Ireland, and the UK), confirmed that the MDA titers in the study calves were representative of typical field conditions [6], lending external validity to the efficacy results and highlighting the pan-European challenge of managing BRSV in the face of maternal immunity.

In summary, the epidemiology of BRSV is characterized by high global seroprevalence, endemic stability, and a complex interplay of risk factors including age, herd size, management type, season, and

Clinical Manifestations and Pathological Features of Bovine Respiratory Syncytial Virus Infection

Spectrum of Clinical Disease and Onset

Bovine Respiratory Syncytial Virus (BRSV) infection presents a strikingly heterogeneous clinical picture, ranging from subclinical infections detected only through molecular or transcriptomic biomarkers to a fulminant, fatal bronchopneumonia. The severity of clinical manifestations is governed by a complex interplay of viral virulence factors, host immune status (particularly the presence and waning of maternally derived antibodies [MDA]), age, concurrent infections, and environmental stressors such as overcrowding and poor ventilation [2, 3, 6]. A hallmark of BRSV is its high contagiousness and its capacity to establish latent foci within herds, with seroprevalence often reaching 60–90% in intensive livestock operations, underscoring its epizootic significance [2, 9]. Although the virus can infect cattle of all ages, the most severe and clinically overt disease is consistently documented in young calves under one year of age, with a peak incidence often observed between 2 and 12 months [16, 25].

The incubation period following natural or experimental exposure is typically short, ranging from 2 to 5 days [6, 8]. The initial clinical signs are often insidious and may be easily mistaken for other common respiratory pathogens. These early manifestations include a sudden onset of pyrexia (fever often reaching 40–41.5°C), serous nasal discharge that rapidly progresses to a mucopurulent character, conjunctivitis, and a dry, harsh cough [3, 8]. As the disease progresses, the cough becomes frequent, moist, and productive. Affected calves exhibit profound depression, anorexia, and a marked disinclination to move. Tachypnea and dyspnea become evident, with pronounced abdominal breathing and extension of the head and neck to facilitate airflow. Upon thoracic auscultation, cranioventral lung fields reveal increased bronchial tones, crackles, and wheezes, indicative of significant lower airway involvement and consolidation. In severe, uncomplicated cases, the respiratory distress can become extreme, leading to open-mouth breathing, frothy salivation, and ultimately, death from respiratory failure within 3–5 days of onset [14, 22]. It is critical to recognize that a substantial proportion of infected animals, particularly within endemic herds where partial immunity exists, may exhibit only mild clinical signs or remain seropositive without overt disease, a phenomenon that complicates outbreak detection and control [2, 8]. Indeed, transcriptomic analyses of whole blood and bronchial lymph nodes from experimentally challenged calves have demonstrated robust gene expression changes, including upregulation of interferon signaling pathways and innate immune responses, even in animals displaying only mild clinical scores, suggesting a significant subclinical or preclinical phase of infection [3, 4, 8].

Gross and Histopathological Lesions

The pathological hallmarks of BRSV infection are centered on the lower respiratory tract, specifically targeting the bronchiolar epithelium and adjacent alveolar parenchyma. At necropsy, the lungs exhibit a characteristic pattern of consolidation, which is classically multifocal and most pronounced in the cranioventral lobes [22]. These consolidated areas are firm, depressed, and dark red to purple in color, contrasting sharply with the surrounding, often emphysematous, lung tissue. The distribution is typically bilateral but not symmetrical. Atelectasis is a prominent gross feature, and on cut section, affected parenchyma is moist and exudes a frothy, serosanguinous fluid from the small airways. The bronchi and trachea frequently contain variable amounts of mucopurulent exudate, edema, and cellular debris.

Histopathological examination reveals a complex triad of lesions: necrotizing bronchiolitis, bronchointerstitial pneumonia, and extensive atelectasis [16, 22]. The earliest and most specific microscopic change is an acute, necrotizing bronchiolitis. The bronchiolar epithelium undergoes extensive degeneration and necrosis, with sloughing of epithelial cells into the airway lumen. This cellular debris, mixed with fibrin, neutrophils, and macrophages, forms characteristic intraluminal plugs that obstruct small airways, contributing to the observed atelectasis and air trapping. There is a concurrent infiltration of the bronchiolar wall and peribronchiolar interstitium by mononuclear cells, predominantly lymphocytes and macrophages, but also neutrophils and plasma cells. The alveolar septae adjacent to affected airways become markedly thickened due to congestion, edema, and infiltration by mononuclear cells, a pattern defined as bronchointerstitial pneumonia [16, 22]. A pathognomonic cellular feature of BRSV infection is the presence of multinucleated syncytial giant cells within the alveolar lumina, alveolar septae, and occasionally within bronchiolar epithelium [16]. These syncytia are formed by fusion of infected epithelial cells and macrophages, driven by the viral fusion (F) glycoprotein, and contain up to 20 or more nuclei. Eosinophilic intracytoplasmic inclusion bodies may also be observed within these syncytial cells and in sloughed bronchiolar epithelial cells, confirming active viral replication. Immunohistochemistry (IHC) studies have demonstrated that BRSV antigens are localized predominantly to the cytoplasm of these epithelial cells, syncytia, and cellular debris within the airways, with only rare antigen detection in deeper alveolar structures [16]. This pattern confirms the virus's primary tropism for the conducting airways.

Systemic Impact and Long-Term Production Consequences

The clinical and pathological impact of BRSV extends far beyond the acute respiratory episode. An exceptionally well-documented study tracking a natural BRSV outbreak in a Norwegian beef herd provided compelling evidence of severe, long-term production losses [14]. Bulls that developed severe clinical signs during the acute outbreak had a significantly and consistently lower weight/age ratio for at least eight months post-infection compared to herdmates with mild or no clinical signs. The growth rate of apparently healthy bulls (those present during the outbreak but without observable clinical signs) was reduced by 111 g/day when compared to a cohort of bulls from the same herd exactly one year later, outside the outbreak period. This translated to an additional 23 days required to reach a reference slaughter weight. Furthermore, feed conversion efficiency was profoundly impaired; the infected cohort demonstrated a reduction of 79 g of weight gain per kilogram of concentrate consumed [14]. These findings underscore that the economic burden of BRSV is not limited to mortality and treatment costs in the acute phase but includes a substantial, often hidden, reduction in lifetime growth performance and productivity in surviving animals. The damage to the lung parenchyma and the chronic inflammation likely lead to compromised pulmonary function and a persistent catabolic state, even after clinical recovery [14, 23]. This is consistent with transcriptomic evidence from lung tissues of coinfected calves, which shows activation of pathways related to tissue repair, such as plasminogen activation and glutathione metabolism, indicating a prolonged host response to resolve the structural damage inflicted by the virus [23]. The virus-induced immunosuppression, characterized by alterations in T-cell responses, leukocyte apoptosis, and dysregulation of cytokine signaling (including interferon and chemokine pathways), also predisposes recovering animals to secondary bacterial infections, further compounding the pathological burden [4, 8, 24]. This progression to viral-bacterial bronchopneumonia is a common and often fatal sequela, where the initial viral insult disrupts mucociliary clearance and innate defenses, allowing opportunistic pathogens like Mannheimia haemolytica and Pasteurella multocida to colonize the lower airways, resulting in a severe, fibrinonecrotizing pleuropneumonia [22, 24].

Advanced Molecular Diagnostics: Multiplex RT-qPCR and Virus Isolation Techniques

The accurate and timely identification of bovine respiratory syncytial virus (BRSV) is paramount for effective disease management, epidemiological surveillance, and the implementation of control strategies within cattle populations. The clinical presentation of BRSV infection, often indistinguishable from other viral agents within the bovine respiratory disease complex (BRDC), necessitates diagnostic modalities that are not only sensitive and specific but also capable of high-throughput analysis [1, 10]. Traditional gold-standard methods such as virus isolation (VI), while indispensable for obtaining live virus for characterization and vaccine development, are inherently time-consuming, technically demanding, and often lack the sensitivity required for detecting low viral loads or compromised samples [1, 10]. In contrast, the advent of advanced molecular diagnostics, particularly multiplex reverse-transcription quantitative polymerase chain reaction (RT-qPCR), has revolutionized the landscape of BRSV detection, offering unparalleled rapidity, sensitivity, and the ability to simultaneously screen for multiple pathogens [1, 13]. This section provides an exhaustive analysis of the current state-of-the-art in multiplex RT-qPCR for BRSV detection and critically examines the complementary role of virus isolation techniques within the modern veterinary diagnostic framework.

Principles and Design of Multiplex RT-qPCR Assays for BRSV

The fundamental principle of multiplex RT-qPCR hinges on the simultaneous amplification and detection of multiple target nucleic acid sequences within a single reaction vessel. This is achieved through the use of multiple sets of primers, each specific to a conserved genomic region of the target pathogen, and distinct fluorophore-labeled probes that allow for the discrimination of each amplicon in real-time [13]. For BRSV, a primary target for primer and probe design is the nucleocapsid (N) gene, which is highly conserved among circulating strains and crucial for viral replication and transcription [1, 15]. The selection of conserved target regions is critical, as genetic drift and recombination, particularly in surface glycoprotein genes like the attachment (G) protein, can lead to mismatches and compromised assay sensitivity [9]. Indeed, phylogenetic analyses have revealed ongoing evolution of BRSV strains, with novel amino acid substitutions identified in the G protein of Turkish isolates [9] and genomic variability even among field strains from different geographical regions [7]. Therefore, robust multiplex assays must be designed against stable genomic regions, such as the N gene, to maintain broad reactivity and diagnostic accuracy across diverse BRSV subgroups, including subgroup III which has been increasingly reported in Europe and Asia [5, 7, 9].

Sophisticated multiplex assays, such as those developed by Thonur et al. (2012) [13], have successfully integrated locked nucleic acid (LNA), minor groove binding (MGB), and conventional TaqMan probes within a single reaction mix for the simultaneous detection of BRSV, bovine herpesvirus 1 (BoHV-1), and bovine parainfluenza virus type 3 (BPI3). This intricate probe design strategy optimizes assay thermodynamics and specificity, enabling highly sensitive detection even in the presence of substantial genetic heterogeneity. The analytical sensitivity of such a multiplex assay was demonstrated to be exceptionally high, detecting as few as 102 copies of the target viral nucleic acid with a clinical sensitivity of 97% when compared to virus isolation and immunofluorescence [13]. More recently, a field-validated multiplex RT-qPCR assay targeting the BRSV N gene and the BPIV3 NP gene achieved a limit of detection (LOD95) of 164 and 359 genome copies, respectively, with amplification efficiencies of 104.2% and 81.6% [1]. This assay not only outperformed virus isolation by detecting 2.4 times more BRSV-positive samples but also demonstrated remarkable reproducibility with coefficients of variation (CV) under 5% [1].

Expanding the Diagnostic Panel: Comprehensive BRDC Pathogen Detection

The clinical reality of BRDC is that it is rarely a mono-infection. Mixed viral and bacterial co-infections are the norm, with BRSV often acting as a primary inciting agent that compromises the host's respiratory defenses, paving the way for secondary bacterial invaders such as Mannheimia haemolytica and Pasteurella multocida [12, 24]. Consequently, the most valuable molecular diagnostic tools are those that can provide a comprehensive syndromic panel. Advanced hexaplex and higher-order multiplex panels have been developed to detect the core viral and bacterial pathogens involved in BRDC, including BRSV, BPIV3, bovine viral diarrhea virus (BVDV), bovine adenovirus type 3 (BAV3), Mycoplasma bovis, and infectious bovine rhinotracheitis virus (IBRV) [12]. Such a comprehensive assay, developed by Li et al. (2025), demonstrated excellent specificity and sensitivity, with detection limits for plasmid standards ranging from 4.99 to 74.4 copies/μL and amplification efficiencies between 93.84% and 111.60% [12]. The clinical application of this assay in 224 natural disease cases revealed a mixed infection rate of 25%, underscoring the critical need for such broad-spectrum diagnostic capacity to guide appropriate therapeutic interventions and management strategies [12]. The use of these advanced multiplex panels provides a holistic view of the BRDC etiology within a herd, allowing veterinarians to identify the dominant pathogens, tailor vaccination protocols, and implement targeted biosecurity measures far more effectively than with single-target assays or traditional culture methods.

The Emergence of Isothermal and Metatranscriptomic Alternatives

While RT-qPCR remains the gold standard for molecular detection in many reference laboratories due to its high throughput and well-established protocols, the veterinary field requires rapid, point-of-care diagnostics that can be deployed in field settings with limited infrastructure. To address this need, isothermal amplification methods, such as reverse-transcription recombinase polymerase amplification (RT-RPA), have been developed. A novel multiplex RT-RPA assay combined with a lateral flow biosensor (mRT-RPA-LFB) was recently established for the simultaneous detection of BRSV, BVDV, and bovine ephemeral fever virus (BEFV) [26]. This assay achieves amplification at a constant temperature of 41°C within 33 minutes, with detection limits as low as 25.6 copies/μL for BRSV [26]. The diagnostic performance of the mRT-RPA-LFB was highly consistent with RT-qPCR (kappa = 0.988), demonstrating its potential as a rapid, accurate, and user-friendly screening tool for field veterinarians and during outbreak investigations [26].

At the other end of the technological spectrum, metatranscriptomic sequencing (RNA-seq) represents a powerful, untargeted approach for detecting both known and emerging viruses in clinical samples. This method sequences all RNA transcripts present in a sample, allowing for the simultaneous identification of any viral pathogen without a priori selection of targets [27]. Early work has quantified the detection limits of metatranscriptomics for bovine respiratory viruses, showing that for BRSV, a sequencing depth of at least 10 million reads is often necessary to detect samples with high RT-qPCR cycle threshold (Ct) values (up to 40), but that high genome coverage is only achieved for samples with Ct < 30 [27]. The choice of reference genome is also critical; using a study-assembled genome significantly increased read counts and coverage compared to a standard reference sequence, a factor particularly relevant for RNA viruses like BRSV which exhibit genetic diversity [9, 27]. While currently more expensive and computationally intensive than qPCR, metatranscriptomics offers the unparalleled advantage of detecting unexpected or novel pathogens, providing invaluable data for genomic epidemiology and surveillance of viral evolution [27].

Virus Isolation: The Indispensable Gold Standard for Characterization

Despite the overwhelming advantages of molecular diagnostics, virus isolation (VI) remains a cornerstone of veterinary virology, particularly for the generation of live viral stocks necessary for detailed biological, antigenic, and pathogenic characterization [1, 7]. Successful isolation of BRSV from clinical specimens, such as lung tissue, nasal swabs, or bronchoalveolar lavage fluid, requires careful optimization of cell culture conditions. BRSV can be propagated in a variety of continuous cell lines, including bovine turbinate (BT), Madin-Darby bovine kidney (MDBK), fetal bovine trachea (FBT), and bovine calf kidney (RBT) cells [7, 25]. The choice of cell line and culture conditions significantly influences viral yield. For instance, studies on the BRSV strain AB1908 demonstrated that optimal viral titers of 4.33–4.78 log10 TCID50/mL were achieved when inoculating 1-2 day-old cell monolayers at a multiplicity of infection of 0.1 TCID50/cell [25]. Similarly, the first isolation of a Turkish BRSV strain (subgroup III) from lung tissue was successfully achieved in MDBK cells, where the characteristic syncytial cytopathic effect (CPE) was observed [7].

However, the process is fraught with challenges. BRSV is notoriously labile, and its successful isolation is highly dependent on the collection, transport, and storage of clinical samples in appropriate viral transport media at low temperatures to preserve infectivity [10]. Many clinical samples that are positive by highly sensitive RT-qPCR often fail to yield live virus, reflecting the presence of non-viable viral particles, low viral loads, or the presence of inhibitory substances [1, 10]. This is particularly evident when comparing detection rates; RT-qPCR consistently detects BRSV at significantly higher frequency than VI [1, 13]. The slow and often subtle development of CPE, which may require multiple blind passages (up to five or more) [31], further limits the utility of VI for rapid clinical diagnosis. Nonetheless, the biological and molecular characterization of new isolates, including full genome sequencing, phylogenetic analysis to determine subgroup classification (e.g., subgroup III) [5, 7, 9], and studies on antigenic diversity and virulence [7], is fundamentally dependent on the successful isolation of the virus. The generation of a pure viral clone through plaque purification is an essential prerequisite for advanced studies, such as evaluating the efficacy of novel vaccine candidates or disinfectants [11, 28].

Synergistic Integration of Diagnostic Technologies

In the modern veterinary diagnostic laboratory, advanced molecular diagnostics and traditional virus isolation are not competing methodologies but rather synergistic tools that serve distinct but complementary purposes. Multiplex RT-qPCR functions as the primary, high-throughput screening tool, providing rapid and sensitive detection to guide immediate clinical decisions and epidemiological investigations [1, 12, 13]. It is the method of choice for large-scale surveillance programs, early outbreak detection, and for assessing the efficacy of control measures and vaccines by monitoring viral shedding in vaccinated versus unvaccinated animals [6, 11]. The remarkable sensitivity of RT-qPCR also makes it ideal for detecting subclinical infections and asymptomatic carriers, which are significant epidemiological drivers of BRSV transmission within herds [2, 3]. Further refining this approach, host transcriptomics or microRNA profiling of whole blood or bronchial lymph nodes has shown promise as a supplementary diagnostic tool, capable of identifying animals with subclinical BRSV infection based on distinct host gene expression signatures even before clinical signs manifest [3, 4, 8].

In turn, virus isolation is reserved for confirmatory purposes on RT-qPCR-positive samples where further characterization is warranted, such as during the investigation of vaccine breakdowns, in the face of outbreaks with unusual clinical severity, or for the generation of regional viral strains for vaccine development and potency testing [11, 29, 30]. The isolated viral stocks can be used for reference purposes, for antigenic cartography to monitor antigenic drift, and for downstream applications such as whole-genome sequencing to track viral evolution and transmission chains with high precision [7, 25]. This integrated diagnostic approach, combining the high sensitivity and throughput of multiplex RT-qPCR with the biological authenticity of virus isolation, provides a robust and comprehensive framework for the control and eventual mitigation of BRSV-associated disease in cattle populations worldwide. The continued development of even more streamlined, field-deployable molecular tools, such as isothermal amplification, will further empower veterinary practitioners and producers in the fight against this economically devastating pathogen [26].

Prevention, Control Strategies, and Vaccine Development for Bovine Syncytial Virus

The development and implementation of robust prevention and control strategies for bovine respiratory syncytial virus (BRSV) remain a paramount challenge for the global cattle industry, given the virus's ubiquitous distribution, high contagiousness, and profound economic impact. Effective management of BRSV necessitates a multifaceted, integrated approach that combines stringent biosecurity measures, strategic diagnostic surveillance, optimized husbandry practices, and, most critically, the deployment of efficacious vaccination protocols. The failure to comprehensively address any single component of this triad can undermine herd-level control, leading to persistent viral circulation, recurrent outbreaks, and substantial production losses that extend far beyond the acute clinical phase [2, 14].

The Rationale for Integrated Control: Epidemiology and Economic Imperatives

Any discussion of control must be grounded in an understanding of BRSV's epidemiological footprint. Seroprevalence surveys consistently reveal that BRSV is endemic in intensive livestock operations worldwide, with infection rates in adult cattle often reaching 60–90% in countries with high-density production systems [2, 25]. A prospective study in the inner Aegean region of Turkey, for example, found that all investigated herds contained at least one seropositive animal, with an overall true individual-level seropositivity of 58.48% [9]. This near-ubiquity is driven by the virus's ability to establish latent or persistent infections within a herd, creating a reservoir of asymptomatic carriers that intermittently shed virus, particularly during periods of stress [2]. The phenomenon of subclinical or mild infections is especially insidious, as genetically susceptible animals, particularly calves under one year of age, may not exhibit overt clinical signs yet still actively transmit the virus, complicating detection through passive observation alone [3, 8, 25].

The economic calculus for BRSV control is compelling. Beyond the immediate costs of veterinary care, mortality, and reduced milk production during acute outbreaks, a carefully documented Norwegian study tracking individual weight gain and feed conversion in beef bulls over an eight-month period following a natural BRSV outbreak revealed profound long-term consequences. Bulls that had exhibited severe clinical signs demonstrated a persistently 0.04–0.10 lower weight/age ratio compared to unaffected contemporaries, a deficit that remained evident throughout the study period [14]. Critically, even apparently healthy bulls that were present during the outbreak but showed no clinical signs suffered a reduced growth rate of 111 g/day, effectively requiring an additional 23 days to reach a reference slaughter weight. Feed conversion efficiency also deteriorated, with a loss of 79 g of weight gain per kilogram of concentrate consumed [14]. These findings underscore that production losses from BRSV are chronically underestimated, persisting long after clinical recovery and affecting animals that never appear sick. Such data provide an undeniable impetus for proactive, rather than reactive, control programs.

Biosecurity and Management-Based Interventions

Fundamental to any control program is the reduction of viral introduction and transmission through rigorous biosecurity. The primary route of BRSV introduction into naive herds is the movement of subclinically infected animals. Consequently, the quarantine of new arrivals, ideally for a minimum of 2–4 weeks, combined with diagnostic screening using sensitive molecular methods such as RT-qPCR, is a critical first line of defense [32]. Within-herd transmission is exacerbated by high stocking densities, poor ventilation, and mixing of animals from different age groups, particularly in enclosed housing systems [24]. Management practices that mitigate these stressors are essential. This includes maintaining optimal air quality, minimizing temperature fluctuations, implementing all-in/all-out management strategies for calf barns, and ensuring that calves receive adequate colostrum to establish passive immunity [24, 33].

The role of environmental decontamination must not be overlooked. BRSV, as an enveloped virus, is susceptible to a range of disinfectants, but efficacy is highly dependent on the specific product, concentration, contact time, and the presence of organic matter. A recent laboratory evaluation of twelve disinfectants against African swine fever virus, a similarly enveloped pathogen, serves as a cautionary tale: several commercially available products failed to demonstrate adequate virucidal activity under the conditions specified in their instructions [28]. This highlights the need for veterinary authorities to enforce rigorous, evidence-based virucidal testing protocols. For BRSV, disinfectants based on quaternary ammonium compounds, aldehydes, or oxidizing agents are generally recommended, but their efficacy must be validated against the specific viral strain and applied in accordance with manufacturer guidelines, with particular attention to pre-cleaning to remove organic debris.

Diagnostic Surveillance as a Cornerstone of Control

The ability to detect BRSV rapidly, accurately, and at minimal cost is a non-negotiable prerequisite for effective control. As discussed in the diagnostic section, the advent of multiplex real-time RT-PCR (mRT-qPCR) has revolutionized surveillance capabilities. These assays, such as those developed by Zulauf and Pastey (2025) targeting the conserved N gene of BRSV and the NP gene of bovine parainfluenza virus-3, offer exquisitely high analytical sensitivity, down to 164 genome copies for BRSV, and the ability to process high sample throughput, making them ideal for both outbreak investigation and routine herd health monitoring [1]. Similarly, a multiplex qPCR panel developed by Li et al. (2025) achieved detection limits for BRSV of 70.1 copies/μL, alongside simultaneous detection of five other major BRD pathogens, enabling a comprehensive etiological assessment from a single reaction [12]. The clinical superiority of molecular methods over traditional virus isolation is unequivocal; the Zulauf and Pastey study demonstrated that RT-qPCR detected 2.4 times more BRSV-positive cases than virus isolation and reliably identified BPIV3-positive cases that would otherwise have been missed [1]. This diagnostic sensitivity is crucial for identifying asymptomatic shedders and implementing timely quarantine measures before an outbreak amplifies.

Beyond nucleic acid detection, non-invasive methods such as transcriptomic or miRNA profiling from whole blood represent a frontier for early subclinical diagnosis. Studies by Johnston et al. have demonstrated that experimental BRSV challenge induces distinct changes in the whole blood transcriptome, 281 differentially expressed genes, and the bronchial lymph node miRNA transcriptome, 119 differentially expressed miRNAs, in calves, even when clinical signs are minimal [3, 4, 8]. These molecular signatures, enriched for pathways such as interferon signaling and pathogen recognition receptor activation, could potentially be harnessed as biomarkers for the diagnosis of subclinical BRSV infection from easily accessible blood samples [3, 8]. The development of such tests would represent a paradigm shift, allowing producers to identify and manage infected animals before they become sources of transmission.

Vaccine Development: Current Arsenal and the Quest for Next-Generation Solutions

Vaccination remains the single most effective tool for preventing BRSV-associated disease and reducing viral shedding within a herd. The landscape of commercial BRSV vaccines is dominated by two broad categories: inactivated (killed) vaccines and modified-live virus (MLV) vaccines. Data from Poland between 2022 and 2024 indicates that inactivated vaccines constitute the majority (50%) of all immunological veterinary medicinal products (IVMPs) licensed for cattle in that country, with BRSV being among the most common viral targets [21]. Surveys of veterinary practitioners in the United States, Canada, and Quebec confirm that BRSV is considered a core vaccine component, with over 90% of veterinarians recommending it as part of routine vaccination protocols for both dairy and beef cattle, often administered in combination with infectious bovine rhinotracheitis (IBR), bovine viral diarrhea virus (BVDV), and parainfluenza-3 (PI3) [34, 35].

Inactivated Vaccine Platforms and Adjuvant Innovation. Inactivated vaccines offer the inherent advantage of safety, as they cannot revert to virulence. However, their immunogenicity is often inferior to MLV vaccines, necessitating the inclusion of potent adjuvants and booster doses. A pivotal study by Fadeel et al. (2020) evaluated a freeze-dried, combined inactivated vaccine (Pneumo-4) containing BRSV, BVDV, BoHV-1, and BPI3V. They demonstrated that the use of carbomer (a synthetic polymer) at 0.3% or 0.5% as a stabilizer, combined with saponin (1 mg/dose) as an adjuvant, significantly enhanced the duration of neutralizing antibody responses. Calves vaccinated with this formulation achieved peak antibody titers at four months post-vaccination, with protective antibody levels persisting for up to nine months, a marked improvement over vaccines stabilized with conventional lactalbumin hydrolysate-sucrose [29]. This extended duration of immunity has substantial practical and economic implications, reducing the number of required vaccinations, associated labor costs, and animal stress. Furthermore, a pilot study by Makoschey et al. (2020) confirmed that co-administration of an inactivated BRD vaccine (containing BRSV, PI3, and Mannheimia haemolytica) with a neonatal calf diarrhea vaccine (containing rotavirus, coronavirus, and E. coli) is safe and does not compromise serological responses to the respiratory components, offering a pragmatic strategy for comprehensive maternal immunization [33].

Modified-Live Intranasal Vaccines: Overcoming Maternal Antibody Interference. One of the most formidable obstacles to effective BRSV vaccination in young calves is the presence of maternally derived antibodies (MDA). Passively acquired antibodies, while protective against disease, can neutralize vaccine antigens, blunting the active immune response. This challenge is particularly acute for systemically administered injectable vaccines. A landmark study by Metcalfe et al. (2020) addressed this directly by evaluating a bivalent MLV intranasal vaccine (Bovalto Respi Intranasal) containing BRSV and PI3V in 10-day-old calves with and without MDA [6]. The results were strikingly clear: intranasal vaccination induced significant protection against subsequent virulent challenge in both MDA-positive and MDA-negative calves. Clinical scores and nasal viral shedding were significantly lower in all vaccinated groups compared to controls (BRSV challenge: clinical scores P=0.016, nasal shedding P=0.002), and there was no statistically significant difference in protection between seropositive and seronegative vaccinates [6]. This outcome is mechanistically driven by the intranasal route, which preferentially elicits a robust mucosal immune response, including secretory IgA antibodies and local T-cell responses, at the portal of entry. This local immunity is less susceptible to systemic MDA interference than systemic IgG responses. The serological survey component of the same study, involving 254 calves from five European countries, confirmed that MDA titers to BRSV and PI3V are widespread at two weeks of age, underscoring the critical importance of this vaccine characteristic for field application [6].

The Next Frontier: Designer Vaccines for Superior Efficacy and DIVA Capability. Despite the availability of commercial vaccines, an articulated unmet need for improved BRSV vaccines with greater efficacy against heterologous strains, longer duration of protection, and the ability to differentiate infected from vaccinated animals (DIVA) persists [20]. The high genetic similarity between BRSV and human RSV (HRSV) has fostered a synergistic research environment, yet patent analyses suggest that cross-utilization of inventions between the human and veterinary fields has been surprisingly limited [20].

Several experimental vaccine candidates are currently under intense investigation, leveraging advanced molecular biology to overcome the limitations of conventional platforms.

• Recombinant Gene-Deleted Vaccines: A particularly promising approach is the development of rationally attenuated vaccines through targeted gene deletion. Blodörn et al. (2014) evaluated a recombinant BRSV with deletion of the small hydrophobic (SH) gene (ΔSHrBRSV) in a proof-of-concept study in calves with MDA [11]. The SH protein is a non-essential virulence factor in RSV; its deletion does not impair viral replication in vitro but attenuates the virus in vivo and reduces pathogenesis. When administered as a single intranasal dose, ΔSHrBRSV conferred almost complete clinical and virological protection against a virulent BRSV challenge five weeks later, despite failing to induce a detectable systemic antibody response prior to challenge [11]. Protection was associated with a rapid and robust anamnestic mucosal IgA, virus-neutralizing antibody, and local T-cell response following challenge. This vaccine is inherently DIVA-compatible, as SH-deleted viruses will not induce antibodies against the SH protein, allowing serological distinction from wild-type virus infection.

• Subunit and Protein-Based Vaccines: The same study by Blodörn et al. also evaluated subunit vaccines based on recombinant HRSV proteins (N, P, and M2-1) engineered to display BRSV F and G epitopes. One formulation (SUMont), adjuvanted with an oil emulsion (Montanide ISA71VG) and administered intramuscularly, induced strong, cross-protective cell-mediated immune responses that provided significant, though not as complete, protection as the ΔSHrBRSV [11]. An alternative formulation (SUAbis), using immunostimulating complex matrices (AbISCO-300), was less effective. These data highlight the critical influence of adjuvant choice and route of administration on the quality and magnitude of the immune response. Furthermore, they demonstrate that a subunit approach targeting internal viral proteins (N, P, M2-1), rather than the surface glycoproteins F and G, can stimulate protective cellular immunity without inducing potentially interfering or non-neutralizing antibodies.

• Recombinant Protein Expression Systems: The production of immunogenic BRSV proteins using recombinant technology offers a scalable, safe, and cost-effective alternative to whole-virus culture. Kolesnikovich and Krasochko (2023) investigated the immunogenicity of a protective F1 protein of BRSV expressed in E. coli (BRSV-F1). In guinea pigs, immunization with bacterial lysates or purified F1 protein, particularly when adjuvanted with IZA-15, elicited specific antibody responses that were not inferior to those induced by a commercial inactivated BRSV vaccine (Bovishield Gold FP 5 L5) [18]. This technology circumvents the risks associated with handling live virus and facilitates the production of DIVA-compatible vaccines, as the immune response is directed only against the selected antigen.

Emerging Non-Vaccine Interventions: Immunomodulation. Alongside vaccine development, strategies to enhance innate resistance to BRSV are gaining traction. A recent investigation by Maina et al. (2023) explored the effects of feeding Saccharomyces cerevisiae fermentation postbiotic products (SCFP) to preweaned calves subsequently co-infected with BRSV and Pasteurella multocida [23]. Transcriptomic analysis of lung tissue revealed that SCFP supplementation modulated the immune response in a beneficial manner: it dampened excessive pro-inflammatory cytokine production (TNF-α and IL-6) in bronchoalveolar cells while upregulating pathways associated with glutathione metabolism and plasminogen, which are critical for lung repair and resolving inflammation [23]. This suggests that SCFP could serve as a nutritional intervention to reduce the severity of BRSV-induced lung pathology, acting synergistically with vaccination to improve overall herd health.

In summary, the prevention and control of BRSV demand a comprehensive strategy that integrates biosecurity, advanced diagnostics, and strategic vaccination. The current vaccine arsenal, while effective, continues to evolve toward next-generation platforms, including gene-deleted MLVs, recombinant subunit vaccines, and immunomodulatory feed additives, that promise to deliver superior, longer-lasting, and DIVA-compatible protection, even in the challenging context of maternally derived antibodies. Future success will depend on the translation of these promising laboratory findings into field-effective products that can be seamlessly integrated into herd health management programs globally.

References

[1] Zulauf B, Pastey M. Field-validated multiplex RT-qPCR for simultaneous detection of bovine respiratory syncytial virus and bovine parainfluenza virus-3 in bovine respiratory samples. Frontiers in Veterinary Science. 2025. DOI: https://doi.org/10.3389/fvets.2025.1645647

[2] Kassen A, Kirpichenko V, Mamanova S, Akshalova P, Zhapbar A, Smailova A, et al.. EPIZOOTIOLOGICAL FEATURES OF THE DISTRIBUTION OF BOVINE RESPIRATORY SYNCYTIAL VIRUS INFECTION: A RETROSPECTIVE ANALYSIS AND DIAGNOSTIC PERSPECTIVES. Ġylym ža̋ne bìlìm. 2025. DOI: https://doi.org/10.52578/2305-9397-2025-3-2-315-329

[3] Johnston D, Earley B, McCabe M, Kim J, Taylor JF, Lemon K, et al.. Messenger RNA biomarkers of Bovine Respiratory Syncytial Virus infection in the whole blood of dairy calves. Scientific Reports. 2021. DOI: https://doi.org/10.1038/s41598-021-88878-1

[4] Johnston D, Earley B, McCabe M, Kim J, Taylor JF, Lemon K, et al.. Elucidation of the Host Bronchial Lymph Node miRNA Transcriptome Response to Bovine Respiratory Syncytial Virus. Frontiers in Genetics. 2021. DOI: https://doi.org/10.3389/fgene.2021.633125

[5] Timurkan M, Aydın H, Sait A. Identification and Molecular Characterisation of Bovine Parainfluenza Virus-3 and Bovine Respiratory Syncytial Virus - First Report from Turkey. Journal of Veterinary Research. 2019. DOI: https://doi.org/10.2478/jvetres-2019-0022

[6] Metcalfe L, Chevalier M, Tiberghien M, Jolivet E, Huňady M, Timothy S, et al.. Efficacy of a live intranasal vaccine against parainfluenza type 3 and bovine respiratory syncytial virus in young calves with maternally derived antibodies. Veterinary Record Open. 2020. DOI: https://doi.org/10.1136/vetreco-2020-000429

[7] Yazici Z, Ozan E, Tamer C, Muftuoglu B, Barry G, Kuruçay H, et al.. Circulation of Indigenous Bovine Respiratory Syncytial Virus Strains in Turkish Cattle: The First Isolation and Molecular Characterization. Animals. 2020. DOI: https://doi.org/10.3390/ani10091700

[8] Johnston D, Earley B, McCabe MS, Lemon K, Duffy C, McMenamy M, et al.. Experimental challenge with bovine respiratory syncytial virus in dairy calves: bronchial lymph node transcriptome response. Scientific Reports. 2019. DOI: https://doi.org/10.1038/s41598-019-51094-z

[9] İnce ÖB, Şevik M, Özgür EG, Sait A. Risk factors and genetic characterization of bovine respiratory syncytial virus in the inner Aegean Region, Turkey. Tropical Animal Health and Production. 2021. DOI: https://doi.org/10.1007/s11250-021-03022-5

[10] Nišavić J, Milić N, Radalj A, Stanojković A, Veljović L. Laboratory diagnostics of bovine parainfluenza-3 virus, bovine herpesvirus 1, and bovine respiratory syncytial virus associated with bovine respiratory disease. Biotehnologija u stocarstvu. 2021. DOI: https://doi.org/10.2298/BAH2101001N

[11] Blodörn K, Hägglund S, Fix J, Dubuquoy C, Makabi-panzu B, Thom M, et al.. Vaccine Safety and Efficacy Evaluation of a Recombinant Bovine Respiratory Syncytial Virus (BRSV) with Deletion of the SH Gene and Subunit Vaccines Based On Recombinant Human RSV Proteins: N-nanorings, P and M2-1, in Calves with Maternal Antibodies. PLoS ONE. 2014. DOI: https://doi.org/10.1371/journal.pone.0100392

[12] Li L, Jiang Q, Li S, Li X, Sun S, Wang X, et al.. Establishment of a multiplex qPCR assay for the detection of pathogens associated with bovine respiratory disease complex. Frontiers in Veterinary Science. 2025. DOI: https://doi.org/10.3389/fvets.2025.1594488

[13] Thonur L, Maley M, Gilray J, Crook TC, Laming E, Turnbull D, et al.. One-step multiplex real time RT-PCR for the detection of bovine respiratory syncytial virus, bovine herpesvirus 1 and bovine parainfluenza virus 3. BMC Veterinary Research. 2012. DOI: https://doi.org/10.1186/1746-6148-8-37

[14] Klem T, Kjæstad HP, Kummen E, Holen H, Stokstad M. Bovine respiratory syncytial virus outbreak reduced bulls’ weight gain and feed conversion for eight months in a Norwegian beef herd. Acta Veterinaria Scandinavica. 2015. DOI: https://doi.org/10.1186/s13028-016-0190-y

[15] Nefedchenko AV, Glotov A, Koteneva S, Glotova T. Developing and Testing a Real-Time Polymerase Chain Reaction to Identify and Quantify Bovine Respiratory Syncytial Viruses. Molecular Genetics Microbiology and Virology. 2020. DOI: https://doi.org/10.3103/S0891416820030052

[16] Flores E, Weiblen R, Medeiros M, Botton S, Irigoyen L, Driemeier D, et al.. A retrospective search for bovine respiratory syncytial virus (BRSV) antigens in histological specimens by immunofluorescence and immunohistochemistry. Pesquisa Veterinaria Brasileira. 2000. DOI: https://doi.org/10.1590/S0100-736X2000000400002

[17] Singh R, Patil RD, Priyanka, Kumar R, Asrani RK, Gupta V, et al.. Prevalence of bovine respiratory viruses in cattle calves in Kangra district of Himachal Pradesh. Indian Journal of Animal Sciences. 2024. DOI: https://doi.org/10.56093/ijans.v94i8.147136

[18] Kolesnikovich KV, Krasochko P. Dynamics of the immune response in laboratory animals to the introduction of a protective protein of the cause of respiratory syncytial infection in cattle. Bulletin of NSAU (Novosibirsk State Agrarian University). 2023. DOI: https://doi.org/10.31677/2072-6724-2023-67-2-205-210

[19] Bashenova E, Kirpichenko V, Nissanova R, Mamanova S, Dyusenov SM, Lesov B, et al.. DIAGNOSIS OF BOVINE VIRAL DIARRHEA: THE IMPORTANCE OF STANDARDIZING CONTROL SERA FOR INTERLABORATORY COMPARISONS. Ġylym ža̋ne bìlìm. 2025. DOI: https://doi.org/10.52578/2305-9397-2025-3-1-237-248

[20] Janse M, Soekhradj SD, Jong Rd, Burgwal LHvd. Identifying Cross-Utilization of RSV Vaccine Inventions across the Human and Veterinary Field. Pathogens. 2022. DOI: https://doi.org/10.3390/pathogens12010046

[21] Pasik K, Borzym E, Nowakowska A, Lysiak E, Nadzieja A, Materek I, et al.. Analysis of current trends in cattle immunoprophylaxis in Poland: national data, European context. Mitteilungen Klosterneuburg : Rebe und Wein, Obstbau und Fruchteverwertung. 2025. DOI: https://doi.org/10.61586/8aniv

[22] . Image Challenge in Veterinary Pathology, Answers: Respiratory Disease. Veterinary Pathology-Supplement. 2020. DOI: https://doi.org/10.1177/0300985820953923

[23] Maina T, McDonald PO, Samuel B, Sardi M, Yoon I, Rogers A, et al.. Feeding Saccharomyces cerevisiae fermentation postbiotic products alters immune function and the lung transcriptome of preweaned calves with an experimental viral-bacterial coinfection.. Journal of Dairy Science. 2023. DOI: https://doi.org/10.3168/jds.2023-23866

[24] Bednarek D, Szymańska-Czerwińska M, Dudek K. Bovine Respiratory Syndrome (BRD) Etiopathogenesis, Diagnosis and Control. . 2012. DOI: https://doi.org/10.5772/33465

[25] Kirpichenko V, Kononova S, Kononov A, Byadovskaya O, Manin B, Sprygin A. CULTURAL PROPERTIES OF BOVINE RESPIRATORY SYNCYTIAL VIRUS STRAIN AB1908. Veterinary Science Today. 2019. DOI: https://doi.org/10.29326/2304-196x-2019-4-31-31-36

[26] Song Y, Ma B, Li J, Shuai J, Zhang M. Multiplex reverse transcription recombinase polymerase amplification combined with lateral flow biosensor for simultaneous detection of three viral pathogens in cattle.. Talanta: The International Journal of Pure and Applied Analytical Chemistry. 2024. DOI: https://doi.org/10.1016/j.talanta.2024.126775

[27] Brito B, Frost M, Webster J, To J, Kirkland PD. Quantifying the impact of sequencing depth and reference genome choice on metatranscriptomic detection of four bovine RNA viruses.. Research in Veterinary Science. 2026. DOI: https://doi.org/10.1016/j.rvsc.2026.106125

[28] Lavrentiev I, Igolkin A, Shevtsov A, Kolbin I, Puzankova O, Gavrilova VL, et al.. Virucidal activity of disinfectants against African swine fever virus. Veterinary Science Today. 2025. DOI: https://doi.org/10.29326/2304-196x-2025-14-2-156-163

[29] Fadeel MRAE, El-Dakhly AT, Farag T, Allam A, Ali N, El-Kholy AA. Protective Value of Freeze-Dried Inactivated Bovine Viral Respiratory Combined Vaccine Stabilized by Carbomer and Adjuvanted with Saponin. Advances in Animal and Veterinary Sciences. 2020. DOI: https://doi.org/10.17582/JOURNAL.AAVS/2021/9.4.525.532

[30] Parreño V, López MV, Rodriguez D, Vena M, Izuel M, Filippi J, et al.. Development and statistical validation of a guinea pig model for vaccine potency testing against Infectious Bovine Rhinothracheitis (IBR) virus. Vaccine. 2010. DOI: https://doi.org/10.1016/j.vaccine.2010.01.035

[31] Berezenko A, Nedosekov V, Godovskiy O, Ltd B. Isolation of bovine coronavirus (BCov) in cell cultures. Naukovì dopovìdì Nacìonalʹnogo unìversitetu bìoresursiv ì prirodokoristuvannâ Ukraïni. 2021. DOI: https://doi.org/10.31548/dopovidi2021.04.001

[32] Socha W, Kołacz P, Rola J. A case of acute respiratory disease associated with Bovine Coronavirus (BCoV) infection in calves at the cattle farm in eastern Poland. Medycyna Weterynaryjna. 2026. DOI: https://doi.org/10.21521/mw.7107

[33] Makoschey B, Vertenten G, Reddick D. The Effect of Co-Administration of Inactivated Vaccines Against Bovine Respiratory Disease and Neonatal Calf Diarrhoea. Folia Veterinaria. 2020. DOI: https://doi.org/10.2478/fv-2020-0017

[34] Fike G, Simroth J, Thomson D, Schwandt E, Spare R, Tarpoff A. A survey of recommended practices made by veterinary practitioners to cow-calf operations in the United States and Canada. The Professional Animal Scientist. 2017. DOI: https://doi.org/10.15232/pas.2017-01642

[35] Morin M, Fecteau G, Roy J, Paradis M, Dufour S. Vaccination protocols in Québec dairy herds.. Journal of Dairy Science. 2024. DOI: https://doi.org/10.3168/jds.2023-24477